Table 3. Summary of Clinical Features of... | American Society of Hematology

Table 3.

Summary of Clinical Features of Patients With WT1 Mutations

Sample	Age	Diagnosis	Cytogenetics	Achieved CR	Clinical Summary
58^*	33	AML M1	No clone	No	Died of refractory disease
87	35	Relapsed AML M0	47 XX +19	—	Died of toxicity
216^*	22	AML M2	No clone	No	Died of refractory disease
232M^*	18	AML M3	Failed	—	Died of cerebral hemorrhage, d 8
146	17	AML M3	47 XY t(15:17) +8, −21	Yes	Died of disease after second relapse
126	6	T-ALL	Normal	Yes	Relapsed 21 months after diagnosis, still on treatment
132^*	25	Biphenotypic	Complex >80	No	Died of refractory disease
101	12	AUL	del (6)(q2), del (11)(p1), add (11)(p1)	?No	Died of disease 1 year after diagnosis

Sample	Age	Diagnosis	Cytogenetics	Achieved CR	Clinical Summary
58^*	33	AML M1	No clone	No	Died of refractory disease
87	35	Relapsed AML M0	47 XX +19	—	Died of toxicity
216^*	22	AML M2	No clone	No	Died of refractory disease
232M^*	18	AML M3	Failed	—	Died of cerebral hemorrhage, d 8
146	17	AML M3	47 XY t(15:17) +8, −21	Yes	Died of disease after second relapse
126	6	T-ALL	Normal	Yes	Relapsed 21 months after diagnosis, still on treatment
132^*	25	Biphenotypic	Complex >80	No	Died of refractory disease
101	12	AUL	del (6)(q2), del (11)(p1), add (11)(p1)	?No	Died of disease 1 year after diagnosis

*See King-Underwood et al5 for further details.